

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

## Sirolimus for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older ID3990

## Final stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Plusultra (sirolimus)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Changing Faces</li> <li>• Genetic Alliance UK</li> <li>• Gene People</li> <li>• Let's Face It</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tuberous Sclerosis Association</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Genetic Nurses &amp; Counsellors</li> <li>• British Association of Dermatologists</li> <li>• British Dermatological Nursing Group</li> <li>• British Geriatrics Society</li> <li>• British Society for Gene and Cell Therapy</li> <li>• British Society for Genetic Medicine</li> <li>• General Medical Council</li> <li>• Neonatal and Paediatric Pharmacists Group</li> <li>• Primary Care Dermatology Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Genetic Testing Network</li> <li>• UK Kidney Association</li> </ul> <p><u>Others</u></p>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Cell and Gene Therapy Catapult</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Great Ormond Street Hospital</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• Paediatric Neurodisability TSC Clinic, Alder Hey Children's Hospital</li> <li>• Paediatric Neurology TSC Clinic, University Hospitals Bristol</li> <li>• Scottish Medicines Consortium</li> <li>• TSC Team, Children's Centre, Royal United Hospital Bath</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Skin Foundation</li> <li>• Cochrane Cystic Fibrosis &amp; Genetic Disorders Group</li> </ul>

Final stakeholder list for the evaluation of sirolimus for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older ID3990

Issue date: December 2023

© National Institute for Health and Care Excellence 2023. All rights reserved Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<ul style="list-style-type: none"> <li>• Cochrane Skin Group</li> <li>• Cochrane UK</li> <li>• Dermatrust</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.

that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.